Elevation of branched-chain amino acid levels in diabetes and NAFL and changes with antidiabetic drug treatment

Summary Diabetes mellitus (DM), non-alcoholic fatty liver (NAFL), and obesity are associated with elevated branched-chain amino acid (BCAA) levels, but the mechanism and significance of this has not been elucidated. Eighty-four subjects were enrolled including 43 with DM. Serum BCAA levels were posi...

Full description

Saved in:
Bibliographic Details
Published in:Obesity research & clinical practice 2015-05, Vol.9 (3), p.293-297
Main Authors: Iwasa, Motoh, Ishihara, Tomoaki, Mifuji-Moroka, Rumi, Fujita, Naoki, Kobayashi, Yoshinao, Hasegawa, Hiroshi, Iwata, Kazuko, Kaito, Masahiko, Takei, Yoshiyuki
Format: Article
Language:English
Subjects:
Aged
Amino Acids, Branched-Chain - antagonists & inhibitors
Amino Acids, Branched-Chain - blood
Antidiabetic drug
Biomarkers - blood
Body Mass Index
Branched-chain amino acid
Diabetes mellitus
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - drug therapy
Diabetes Mellitus, Type 2 - physiopathology
Endocrinology & Metabolism
Female
Glycated Hemoglobin A - analysis
Humans
Hypoglycemic Agents - therapeutic use
Insulin Resistance
Internal Medicine
Japan
Liver - diagnostic imaging
Liver - physiopathology
Male
Middle Aged
Non-alcoholic fatty liver
Non-alcoholic Fatty Liver Disease - blood
Non-alcoholic Fatty Liver Disease - complications
Non-alcoholic Fatty Liver Disease - diagnostic imaging
Non-alcoholic Fatty Liver Disease - physiopathology
Obesity
Obesity - complications
Piperidines - therapeutic use
Thiazolidinediones - therapeutic use
Ultrasonography
Up-Regulation - drug effects
Uracil - analogs & derivatives
Uracil - therapeutic use
Waist-Hip Ratio
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Diabetes mellitus (DM), non-alcoholic fatty liver (NAFL), and obesity are associated with elevated branched-chain amino acid (BCAA) levels, but the mechanism and significance of this has not been elucidated. Eighty-four subjects were enrolled including 43 with DM. Serum BCAA levels were positively correlated with waist–hip ratio and ALT. Serum BCAA levels in subjects with DM were higher than non-DM and those in subjects with NAFL were also higher than non-NAFL. Treatment with pioglitazone and alogliptin (19 of 43 DM subjects) improved serum haemoglobin A1c and decreased BCAA levels. The decrease in BCAAs with improved glucose metabolism suggests that abnormal glucose metabolism is also a factor in elevated BCAA levels.
ISSN:1871-403X
1878-0318
DOI:10.1016/j.orcp.2015.01.003